T-Therapeutics Raises $133M for TCR Clinical Development

Kirsty Crame has a consequential assignment at T-Therapeutics: carry a discovery platform's possibilities into clinical development. The Cambridge biotechnology company announced a $133M Series B on November 5, 2026, financing 2 lead programmes in cancer and autoimmune disease through planned clinical proof of concept.

Advent Life Sciences and British Business Bank co-led the financing, reported by Advent as £100M ($133M). CEO Theodora Harold and founder and CSO Allan Bradley are directing a company whose next stage depends on turning target-selection expertise into medicines that can be studied in people. Crame, the Chief Development Officer whose appointment was announced alongside the round, is responsible for translational and clinical development.

The financing connects specialist venture investors, pharmaceutical capital and a UK public development bank around that transition. Their investment supports a demanding scientific ambition: use T cell receptors to reach disease targets that conventional antibody approaches have struggled to address, then apply the resulting medicines across solid tumours and autoimmune conditions. Clinical benefit remains an objective of the work being financed.

What the Series B finances

T-Therapeutics says the proceeds will support clinic entry and clinical proof-of-concept data for its 2 lead TCR-CD3 bispecific programmes. Its financing announcement names Johnson & Johnson Innovation – JJDC, Samsara BioCapital, M-Ventures and Eli Lilly and Company as additional new investors. Existing major shareholders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF also participated.

The company had expanded its Series A to $91M in November 2025, adding $32M to the original $59M. That history gives the new round a specific place in the development sequence: earlier financing supported advancement toward the clinic, while the Series B explicitly funds the pursuit of clinical proof of concept. No valuation was disclosed in the reviewed announcements, and the releases do not provide a spending allocation between programmes.

Cooley, which advised T-Therapeutics on the transaction, separately confirms that the oversubscribed round closed. The legal milestone is settled; the programmes' development milestones remain ahead. Investors are financing a company preparing to produce a different kind of evidence from the discovery work that established its platform.

Why T cell receptor selection matters

T-Therapeutics' pipeline description explains the opportunity through the fragments of proteins its receptors recognise. Those peptides can originate from proteins inside a cell, expanding the available target space beyond conventional antibody approaches. The important commercial possibility is access to disease biology that a drug developer previously struggled to reach.

The company's OpTiMus platform supplies fully human T cell receptors for selection and engineering. T-Therapeutics describes using yeast display, machine learning and structural prediction to identify molecules with the binding properties it wants. Its T-Bridge format combines an engineered receptor with a CD3 binder and an Fc region, bringing target recognition and T cell recruitment into the same therapeutic design.

That architecture creates several connected engineering decisions. T-Therapeutics says its CD3 binders are designed to retain killing activity while limiting cytokine release, and its format aims to support a useful half-life and dosing schedule. These are descriptions of the company's design goals, rather than demonstrated patient outcomes for the lead programmes.

For investors assessing the platform, the relationship between breadth and selection is central. A larger supply of candidate receptors creates more possibilities, while clinical development commits resources to particular molecules and indications. The Series B puts money behind those choices, with 2 lead programmes carrying the immediate development assignment.

Two disease areas, different biological jobs

The oncology programme is aimed at solid tumours, an area the financing announcement identifies as a major opportunity for T cell engager approaches. In autoimmune disease, the company seeks to remove pathogenic cells responsible for chronic tissue inflammation. The shared platform therefore serves distinct biological objectives, with target choice shaping what the recruited T cells are being asked to do.

T-Therapeutics describes the immunology approach as a precision immune reset and says both lead programmes could address multiple indications. Those ambitions help explain the financing's scope, but the announcement does not establish efficacy across those indications or supply patient results. Readers can understand the intended reach without treating the potential market as an already demonstrated treatment franchise.

The British Business Bank's account of its investment places T-Therapeutics within its support for UK university spinouts and the commercialisation of research. That gives the syndicate another perspective alongside pharmaceutical and specialist venture capital: the ability of a Cambridge company to carry its science into a larger development organisation.

For prospective partners, the financing brings those scientific and institutional relationships together around identifiable programmes. The useful reading of the round is programme-specific: oncology and immunology share discovery capabilities, while each still requires development evidence suited to the disease biology it intends to change.

The people carrying the platform into development

T-Therapeutics was founded in 2022 and spun out of the University of Cambridge. A Cambridge Enterprise founder record identifies Allan Bradley, Wei Wang, Hanif Ali, Qunwei Wang and Haydn Prosser as founders. Bradley remains founder and CSO; the current company leadership page does not establish executive roles for the other historical founders.

Theodora Harold's company biography dates her CEO appointment to March 2025 and records her previous leadership of Crescendo Biologics. Bradley brings a history in Cambridge research, Sanger Institute leadership and biotechnology company formation. Their responsibilities now sit alongside Crame's clinical-development remit, creating a leadership structure around the transition the financing supports.

Crame's biography describes experience at Curatis, Medigene and Gadeta, including TCR-targeted and early clinical programmes. The appointment is relevant to the work immediately ahead: translational strategy and clinical execution for the bispecific pipeline. Her experience connects the company's selection of molecules with the organisation needed to study them.

At One Granta in Cambridge, that development organisation now has a larger syndicate behind it. The next movement belongs to the individual programmes: choosing where the platform's target access can become a clinically useful intervention, and carrying those decisions through the studies this financing is intended to support.